Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA d... ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany. Mehr anzeigen
- Srinivas Rao M.D., Ph.D. succeeds as sole Chief Executive Officer- Kevin Craig, M.D. promoted to Chief Medical Officer- Glenn Short, Ph.D. promoted to Chief Scientific Officer- Gerd...
- The United States Food and Drug Administration cleared the investigational new drug application for VLS-01 (buccal film DMT); atai expects to initiate a Phase 2 study in treatment-resistant...
GAITHERSBURG, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Greg Weaver as Chief Financial...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.1953 | 14.0503597122 | 1.39 | 1.6 | 1.3863 | 885907 | 1.49081131 | CS |
| 4 | 0.3154 | 24.8366013072 | 1.2699 | 1.91 | 1.21 | 1837226 | 1.5575668 | CS |
| 12 | 0.5253 | 49.5566037736 | 1.06 | 1.95 | 1.05 | 1807504 | 1.50509887 | CS |
| 26 | -0.0147 | -0.91875 | 1.6 | 1.95 | 1.03 | 1120254 | 1.42584461 | CS |
| 52 | -0.2847 | -15.2245989305 | 1.87 | 2.85 | 1.03 | 1197825 | 1.68256746 | CS |
| 156 | -3.4397 | -68.4517412935 | 5.025 | 6.32 | 1.025 | 1051933 | 2.30661027 | CS |
| 260 | -0.2447 | -13.3715846995 | 1.83 | 22.91 | 1.025 | 826380 | 3.42531412 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
